BCYC insider buying – Bicycle Therapeutics Plc
8 insider purchases since 2016 worth $56.3M by 8 different insiders. Last 12 months: 0 purchases, $0. Most recent filing: 2024-12-17.
Same time range as the chart above - each mark sits under the week of the trade. Circles = purchases (height = price paid, size = amount), red triangles = open-market sales of $50k+. Prices as reported, not adjusted for later stock splits. 7 older purchases (before the 5-year window) are listed in the table below.
Purchases are open-market buys (SEC Form 4, code "P") - insiders paying with their own money. Sales are open-market sales (code "S") of $50,000 or more; many sales are pre-planned (Rule 10b5-1) or made for taxes and diversification. Each row links to the original filing.
Bought, sold, still holding?
| Insider | Bought | First / last buy | Sold since 2016 | Holds now* | Status |
|---|---|---|---|---|---|
| Baker Bros. Advisors (GP) LLC Director | $21.2M 1× · 1,485,397 sh | 2024-12-13 2024-12-13 | – | 8,666,247 shares as of 2024-12-17 | Holds - never sold |
| NG CAROLYN Director | $8.0M 1× · 571,429 sh | 2019-05-27 2019-05-27 | – | 1,427,151 shares as of 2019-05-31 | Holds - never sold |
| BINGHAM KATE Director | $5.4M 1× · 385,715 sh | 2019-05-28 2019-05-28 | 1× · $1.5M last 2021-07-13 | 1,913,757 shares as of 2021-07-20 | Sold part |
| GLAXOSMITHKLINE PLC Director | $5.4M 1× · 385,714 sh | 2019-05-28 2019-05-28 | 1× · $91,814 last 2020-07-14 | 1,913,678 shares as of 2020-09-18 | Sold part |
| AQUILA INVESTMENTS IV 10% Owner | $5.1M 1× · 364,286 sh | 2019-05-28 2019-05-28 | – | 1,454,411 shares as of 2019-06-03 | Holds - never sold |
| Cambridge Innovation Capital (Jersey) Ltd 10% Owner | $4.4M 1× · 314,286 sh | 2019-05-29 2019-05-29 | – | 1,751,437 shares as of 2019-05-31 | Holds - never sold |
| Anstey Michael Director | $4.4M 1× · 314,286 sh | 2019-05-28 2019-05-28 | – | 1,081,823 shares as of 2019-05-30 | Holds - never sold |
| Novartis Bioventures Ltd 10% Owner | $2.4M 1× · 168,630 sh | 2019-05-28 2019-05-28 | – | 1,601,011 shares as of 2019-05-30 | Holds - never sold |
* Shares held after the insider's most recent SEC filing for this company (all share classes, direct and indirect). If an insider stops filing, later changes are not known.
Insider buying and selling by year
| Year | Purchases | Bought | Buyers | Sales | Sold |
|---|---|---|---|---|---|
| 2026 | 0 | – | – | 2 | $191,688 |
| 2025 | 0 | – | – | 6 | $498,522 |
| 2024 | 1 | $21.2M | 1 | 5 | $518,837 |
| 2023 | 0 | – | – | 4 | $332,243 |
| 2021 | 0 | – | – | 30 | $25.7M |
| 2020 | 0 | – | – | 3 | $797,674 |
| 2019 | 7 | $35.1M | 7 | – | – |
Insider purchases
| Filed | Insider | Role | Shares | Avg price | Value | Holdings | Filing |
|---|---|---|---|---|---|---|---|
| 2024-12-17 | Baker Bros. Advisors (GP) LLC | Director | 1,485,397 | $14.29 | $21.2M | +17.5% | SEC |
| 2019-06-03 | AQUILA INVESTMENTS IV | 10% Owner | 364,286 | $14.00 | $5.1M | +22.9% | SEC |
| 2019-05-31 | Cambridge Innovation Capital (Jersey) Ltd | 10% Owner | 314,286 | $14.00 | $4.4M | +21.9% | SEC |
| 2019-05-30 | Novartis Bioventures Ltd | 10% Owner | 168,630 | $14.00 | $2.4M | +10.5% | SEC |
| 2019-05-30 | GLAXOSMITHKLINE PLC | Director | 385,714 | $14.00 | $5.4M | +25.2% | SEC |
| 2019-05-30 | BINGHAM KATE | Director | 385,715 | $14.00 | $5.4M | +25.9% | SEC |
| 2019-05-30 | Anstey Michael | Director | 314,286 | $14.00 | $4.4M | +21.9% | SEC |
| 2019-05-30 | NG CAROLYN | Director | 571,429 | $14.00 | $8.0M | SEC |
Insider sales
| Filed | Insider | Role | Shares | Avg price | Value | Type | Filing |
|---|---|---|---|---|---|---|---|
| 2026-01-06 | Young Alethia | CFO | 7,623 | $6.62 | $50,489 | Pre-planned (10b5-1) | SEC |
| 2026-01-06 | Lee Kevin | CEO | 21,314 | $6.62 | $141,199 | Sale | SEC |
| 2025-01-06 | Thompson Travis Alvin | Officer | 4,595 | $14.64 | $67,293 | Pre-planned (10b5-1) | SEC |
| 2025-01-06 | Skynner Michael | Officer | 4,223 | $14.24 | $60,120 | Sale | SEC |
| 2025-01-06 | Milnes Alistair | Officer | 5,514 | $14.20 | $78,310 | Sale | SEC |
| 2025-01-06 | Lee Kevin | CEO | 12,130 | $14.26 | $172,952 | Sale | SEC |
| 2025-01-06 | Crockett Nigel | Officer | 3,519 | $14.27 | $50,200 | Sale | SEC |
| 2025-01-06 | Arroyo Santiago | Officer | 4,943 | $14.09 | $69,647 | Sale | SEC |
| 2024-11-13 | Thompson Travis Alvin | Officer | 6,256 | $25.11 | $157,114 | Pre-planned (10b5-1) | SEC |
| 2024-10-04 | Lee Kevin | CEO | 3,212 | $22.26 | $71,499 | Sale | SEC |
| 2024-07-08 | Lee Kevin | CEO | 3,194 | $19.64 | $62,730 | Sale | SEC |
| 2024-04-05 | Lee Kevin | CEO | 3,158 | $23.81 | $75,192 | Sale | SEC |
| 2024-01-04 | Lee Kevin | CEO | 8,703 | $17.50 | $152,302 | Sale | SEC |
| 2023-01-05 | Skynner Michael | Officer | 1,801 | $29.06 | $52,337 | Sale | SEC |
| 2023-01-05 | Lee Kevin | CEO | 6,000 | $29.06 | $174,360 | Sale | SEC |
Showing the latest 15 of 50 sales of $50,000+ since 2016.
Compiled automatically from public SEC filings. Not investment advice. Get every new insider purchase in the daily report.
Get every new insider purchase the day it's filed
Daily report with all SEC insider buys, cluster buys, company events and the crypto money-flow radar.
Get started free